Neuronetics (STIM) closed at $2.01 on November 10, 2026, down 7.8% from the previous close, on volume of 1,009,218 shares (30-day average 1,094,293).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Neuronetics prices $30M public offering, shares slide 13%
Seeking Alpha News (Wed, 11-Nov 2:07 AM ET)
Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
Globe Newswire (Tue, 10-Nov 10:39 PM ET)
Neuronetics Amends Credit Agreement and Revenue Covenants
TipRanks (Tue, 10-Nov 4:37 PM ET)
Neuronetics falls in after-hours after launching a public stock offering
Seeking Alpha News (Tue, 10-Nov 4:11 PM ET)
Neuronetics Announces Proposed Public Offering of Common Stock
Globe Newswire (Tue, 10-Nov 4:01 PM ET)
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 4-Nov 4:30 PM ET)
Neuronetics Rallies After Q3: Greenbrook Revenue Rose 20.1% and Operating Income Turned Positive
Market Chameleon (Wed, 4-Nov 6:51 AM ET)
Neuronetics Reports Third Quarter 2026 Financial and Operating Results
Globe Newswire (Wed, 4-Nov 7:50 AM ET)
Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call
Globe Newswire (Wed, 21-Oct 8:30 AM ET)
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
Globe Newswire (Tue, 8-Sep 8:32 AM ET)
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Neuronetics trades on the NASDAQ stock market under the symbol STIM.
As of November 11, 2026, STIM stock price declined to $1.71 with 5,825,245 million shares trading.
STIM has a beta of 3.00, meaning it tends to be more sensitive to market movements. STIM has a correlation of 0.11 to the broad based SPY ETF.
STIM has a market cap of $130.30 million. This is considered a Micro Cap stock.
Last quarter Neuronetics reported $42 million in Revenue and -$.02 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.08.
In the last 3 years, STIM traded as high as $5.92 and as low as $.52.
The top ETF exchange traded funds that STIM belongs to (by Net Assets): VTI, PSIL, VXF, BUSM, IWC.
STIM has underperformed the market in the last year with a price return of -20.1% while the SPY ETF gained +12.8%. STIM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.2% and -21.9%, respectively, while the SPY returned -1.3% and -1.1%, respectively.
STIM support price is $1.88 and resistance is $2.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STIM shares will trade within this expected range on the day.
